Oxlumo 94.5 mg/0.5 mL injection Images
Generic Name: lumasiran
This medication has been identified as Oxlumo 94.5 mg/0.5 mL injection. It is supplied by Alnylam Pharmaceuticals, Inc.
Oxlumo is used in the treatment of Primary Hyperoxaluria and belongs to the drug class miscellaneous metabolic agents. Oxlumo 94.5 mg/0.5 mL injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Oxlumo
- Generic Name
- lumasiran
- Strength
- 94.5 mg/0.5 mL injection
- Availability
- Prescription only
- Drug Class
- Miscellaneous metabolic agents
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Alnylam Pharmaceuticals, Inc.
- National Drug Code (NDC)
- 71336-1002
See also:
Rivfloza
Rivfloza (nedosiran) is a medication used to treat primary hyperoxaluria type 1 (PH1) that works to ...
Amvuttra
Amvuttra is used to treat polyneuropathy associated with hereditary transthyretin-mediated ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Aqneursa
Aqneursa information from Drugs.com, includes Aqneursa side effects, interactions and indications.
Cerdelga
Cerdelga (eliglustat) is used to treat mild to moderate Type 1 Gaucher Disease. Includes Cerdelga ...
Crysvita
Crysvita is used for familial hypophosphatemia, osteomalacia, X-Linked Hypophosphatemia
Galafold
Galafold (migalastat) is used to treat Fabry disease. Includes Galafold side effects, interactions ...
Givlaari
Givlaari injection is used for acute hepatic porphyria (AHP) to reduce the number of acute attacks ...
Iqirvo
Iqirvo (elafibranor) is used to treat primary biliary cholangitis (PBC) in combination with ...
More about Oxlumo (lumasiran)
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous metabolic agents
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.